Pharmacy Industry Leadership: An Overview of USP - February 22, 2014 10:30 - 11:30 AM

Page created by Cathy Hammond
 
CONTINUE READING
Pharmacy Industry Leadership: An Overview of USP - February 22, 2014 10:30 - 11:30 AM
February 22, 2014
10:30 – 11:30 AM

Pharmacy Industry Leadership: An
Overview of USP
                         Jeanne Sun, Pharm.D.
                      Associate Scientific Liaison
                    Healthcare Quality Standards
Pharmacy Industry Leadership: An Overview of USP - February 22, 2014 10:30 - 11:30 AM
USP’s Beginning

  USP was founded in 1820 by
11 physicians, in Washington, D.C.

                                     2
Pharmacy Industry Leadership: An Overview of USP - February 22, 2014 10:30 - 11:30 AM
The first Pharmacopeia (1820)

The first Pharmacopoeia of the United States contained 217 of the
“most fully established and best understood” medicines in the
U.S. It was published “by the authority of the medical societies
and colleges.”
                                                                    3
Pharmacy Industry Leadership: An Overview of USP - February 22, 2014 10:30 - 11:30 AM
About USP

   Scientific non-profit
    organization that sets
    standards for the identity,
    strength, quality, and purity of
    medicines, food ingredients,
    and dietary supplements

                                                            USP Headquarters
                                                                Rockville, MD

    USP’s Mission:
    To improve global health through public standards and related
    programs that help ensure the quality, safety, and benefit of
    medicines and foods.
                                                                                4
Pharmacy Industry Leadership: An Overview of USP - February 22, 2014 10:30 - 11:30 AM
About USP

   What We Do Today
    – Establish and disseminate public written standards for the quality,
      purity, identity, strength, and labeling of medicines
    – Provide recommendations to practitioners on the safe use of
      medicines
    – Work with international health agencies to improve the quality of
      medicines worldwide
    – Educate practitioners, producers and others seeking information on
      quality and USP standards

                                                                            5
Pharmacy Industry Leadership: An Overview of USP - February 22, 2014 10:30 - 11:30 AM
Council of Experts

                     6
Pharmacy Industry Leadership: An Overview of USP - February 22, 2014 10:30 - 11:30 AM
USP Standards

   The United States Pharmacopeia National
    Formulary (USP–NF)
   Food Chemicals Codex (FCC)
   USP Dietary Supplements
    Compendium (DSC)
   USP on Compounding
   USP Medicines Compendium (MC)
   Herbal Medicines Compendium (HMC)
   Reference Standards
   Other Resources
    –   Pharmacopeial Forum (PF)
    –   FCC Forum (FCCF)
    –   USP Dictionary
    –   Chromatographic Columns

                                              7
Pharmacy Industry Leadership: An Overview of USP - February 22, 2014 10:30 - 11:30 AM
Legal Recognition Around the World

   USP standards are used in more than 140 countries around the
    world.

   Medicines                            Food Ingredients
    – Exportation of medicines to        The Food Chemicals Codex (FCC)
      the U.S. should abide by U.S.       compendium are recognized in:
      law and U.S. FDA                      Canada – food additive must
      regulations, which specify              comply with specifications in
      USP–NF standards.                       FCC
                                            Australia and New Zealand –
                                              primary source of identity and
                                              purity specifications for
                                              substances added to food
                                            Brazil – FCC standards are
                                              recommended, along with
                                              other standards.
                                            Israel – food additive must
                                              comply with FCC or iJECFA.

                                                                               8
Pharmacy Industry Leadership: An Overview of USP - February 22, 2014 10:30 - 11:30 AM
Legal Recognition in the US

 1848 Drug Import Act                1994 Dietary Supplement
 recognized USP standards to          Health Education Act
 stop the dumping of drugs by         recognize USP standards for
 Europeans                            dietary supplements

 1906  Pure Food and Drugs Act
 enforced USP and NF standards
 for strength, quality, and purity

 1938 Food, Drug and
 Cosmetic Act recognized USP
 & NF standards for strength,
 quality, purity, packaging, and
 labeling

                                                                    9
                                                                        9
Pharmacy Industry Leadership: An Overview of USP - February 22, 2014 10:30 - 11:30 AM
Legal Recognition in the US

 1997FDA Modernization Act         2013Drug Quality and
 Sec. 503A stated that              Security Act recognize USP
 compounding must comply with       monographs for bulk drug
 USP-NF standards and chapter       substances and USP chapters
 on pharmacy compounding            on pharmacy compounding

 2003Medicare Modernization
 Act requested USP to develop
 and revise the Model Guidelines
 for Medicare Formularies

 2010Affordable Care Act
 recognizes USP Model
 Guidelines to assess coverage
 of Essential Health Benefits

                                                                  10
                                                                       10
USP Healthcare Quality Standards

   Expert Committees (2010-2015)
    – Nomenclature, Safety and Labeling Expert Committee
        • Scientific Liaison: Andrzej Wilk, Ph.D.
        • Scientific Liaison: Donna Bohannon, R.Ph.
    – Compounding Pharmacy Expert Committee
        • Scientific Liaison: Rick Schnatz, Pharm.D.
        • Scientific Liaison: Jeanne Sun, Pharm.D
    – Therapeutic Information and Formulary Support
         • Scientific Liaison: Jami Earnest, Pharm.D
   Expert Panels and Advisory Groups
    – Prescription Container Labeling
    – Compounding with Hazardous Drugs
    – Pharmaceutical Compounding – Sterile Preparations

                                                           11
Nomenclature, Safety and
Labeling Expert Committee
Monograph Titles

1.   Substance monograph
       Amlodipine Besylate

2.   Product monograph
       Amlodipine Besylate
       Tablets

3.   Compounded Preparation
     monograph
       Amlodipine Oral
       Suspension

                              13
USP Dictionary

 Entry   Components
 – U.S. Adopted Name (USAN)
 – Pronunciation Guide
 – Molecular formula and weight
 – Chemical Name
 – CAS registry number(s)
 – Other nonproprietary names
 – Pharmacologic and/or therapeutic activity
 – Brand name(s)
 – Name(s) of manufacturer
 – Graphic formula

                                               14
Reference Tables

   Container for Dispensing Capsules and Tablets
    – Relevant tight (T)
    – Well-closed (W)
    – Light-resistant (LR)

   Solubility

   Atomic weights

                                                    15
Prescription Container Labeling

   Purpose
    – To develop standards for prescription container labels as they are the
      patient’s best source. The prescription container label must be able to
      fulfill the professional obligations of the healthcare provider to give
      the patient all the information needed to understand how to safely
      use the medication

   Official May 2013

                            Take:
                               2 tablets in the morning
                               2 tablets in the evening

                                                                            16
Physical Environments that Promote
            Safe Medication Use
   Purpose
    – To describe optimal physical environment standards to promote
      accurate medication use and improve performance since the work
      environment has been identified as one of the most commonly
      reported factors contributing to medication errors

   Physical Environments addressed:
    –   Illumination
    –   Sound and Noise
    –   Interruptions and Distractions
    –   Physical Design and Organization
        of Workspace

                                                                       17
Safety Focused Labeling Initiatives

 Ferrules   and Cap Overseals

 Strength   and Total Volume

 Prescription   Container Labeling

                                               18
USP Pictograms

 Standardized  graphic images that help convey medication
 instructions, precautions, and/or warnings to patients and consumers.
 – Deliver important information to patients with a lower level reading ability and
   patients for whom English is a second language.
 – Reinforce printed or oral instructions.

 Currently   USP offers 81 pictograms
 – Tested for comprehension

 Available   for download (free of
 charge)
 – http://www.usp.org/usp-healthcare-
   professionals/related-topics-resources/
   usp-pictograms

                                                                                      19
Compounding Expert
Committee
Compounding

 Definition
 – The preparation of a drug in accordance with a licensed practitioner’s
   prescription or medication order based on the triad relationship.

 Why   compound?                      Viable   Alternatives?
 – Pediatric patients                  – Crushing Tablets
 – Geriatric patients                  – Splitting Tablets
 – Animal patients                     – IV Solutions
 – Non-standard doses
 – Allergen-free medication
 – HRT
 – Sports Injuries
 – Pain management
 – Drug Shortages
 – Discontinuation by manufacturer

                                                                            21
                                                                                 21
Compounding General Chapters

    Pharmaceutical Compounding – Nonsterile Preparations

    Pharmaceutical Compounding-Sterile Preparations

    Quality Assurance in Pharmaceutical Compounding

    Pharmaceutical Calculations in Prescription Compounding

   Prescription Balances & Volumetric Apparatus

                                                                     22
Hazardous Drugs – Handling in
           Healthcare Settings
   Purpose
    – To clearly identify the requirements for handling of hazardous drugs
      to protect the patient, healthcare personnel, and environment.
    – Processes intended to provide containment of HDs to as low a limit
      as reasonably achievable
    – Harmonization of OSHA , NIOSH,
      ASHP, and ONS guidelines

    – Addresses receipt, storage, mixing,
      preparing, compounding (sterile and
      nonsterile), dispensing, and
      administration of hazardous drugs

                                                                             23
Compounding for Investigational
         Studies
 Purpose:
 – To guide compounding practitioners in the extemporaneous compounding of
   drugs used in investigational studies.
   – Should be in compliance with all the appropriate USP general chapters
     and USP–NF standards pertaining to compounding
   – Chapter provides additional standards for compounding for investigational
     preclinical and early phase I investigations

 New   chapter proposal for PF39(5)     Sept-Oct 2013
 – Targeted publication in USP37-NF32 (2nd Supplement)

                                                                                 24
Compounded Preparation Monographs

   COMPOUND PILLS OF JALAP

Take of Jalap in powder;
        Rhubarb in powder;
        Castile soap, each one ounce.
        Submuriate of mercury six drachms
  and two scruples.
        Tartarized antimony, twenty eight
  grains.

With water form a mass and divide into four
  hundred pills.
Components of a Compounded Preparation
              Monograph

 Title
 Definition
    -   Lists the range of labeled amount
        of active ingredient
 Formula
    -   Ingredients and quantities
 Compounding Procedures
 Stability-indicating Assay
 pH
 Packaging and Storage
 Labeling
 Beyond-use dates
    -   Stability studies
    -   Chapters  or 

                                                       26
Clinical Case

 S:   Malnourished white male
       At 3 months, developed “cradle cap”

 O: At 6 months, weighed 4 pounds
       Widespread weeping cutaneous lesions covering body
       Seizures and Impaired digestion

 A:
 P:

 Acrodermatitis enteropathica is an autosomal recessive metabolic
 disorder affecting the uptake of zinc, characterized by periorificial and acral
 dermatitis, alopecia, and diarrhea. Fatal if untreated.
                                                                                   27
Clinical Case

                                                                                    Zinc Sulfate 44 mg/mL
123	
  Pharmacy	
  Road	
  
Rockville,	
  MD	
                                                                  Solution
(123)555-­‐0123	
  
                                                                                    Zinc sulfate, granular                           4.4 g
Name:	
  Baby Johnson                                                Age:	
  	
     (heptahydrate)
6 months
Date:	
  June 26, 2013                                                              Cherry syrup, NF                                45 mL
                                                                                    Purified Water, NF, a                          100 mL
     Zinc Sulfate 44 mg/mL
                                                                                    sufficient quantity to
          Oral Solution
                                                                                    make
Sig: 3.5 mL/day of zinc                                                             Note:	
  Elemental	
  zinc	
  1	
  mg	
  is	
  equivalent	
  
(equiv 154 mg/day Zinc)                                                             to	
  zinc	
  sulfate	
  2.47	
  mg	
  or	
  zinc	
  sulfate	
  
Disp: 50 mL                                                                         heptahydrate	
  4.4	
  mg.	
  

ReLills: 3 	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  Signature:	
  Dr. Smith
Therapeutic Information and
Formulary Support Expert
Committee

                              29
Medicare Modernization Act (MMA) 2003

   Section 1860D-4(b)(3)(C) defines role of USP:
   “(ii) MODEL GUIDELINES The [HHS] Secretary shall request the United States
    Pharmacopeia to develop, in consultation with pharmaceutical benefit managers
    and other interested parties, a list of categories and classes that may be used by
    prescription drug plans under this paragraph and to revise such classification
    from time to time to reflect changes in therapeutic uses of covered part D drugs
    and the additions of new covered part D drugs.”
   Section 1860D-11(e)(2)(D) creates “safe harbor”:
   “(ii) USE OF CATEGORIES AND CLASSES IN FORMULARIES. The Secretary
    may not find that the design of categories and classes within a formulary violates
    clause (i) if such categories and classes are consistent with guidelines (if any) for
    such categories and classes established by the United States Pharmacopeia.”
USP Medicare Model Guidelines
       Development

                                        USP MMG v1.0 (2005)
                                         involved:
                                         –   Expert Committee
                                         –   Environmental scan
                                         –   Public advisory meetings
                                         –   Public comment process
                                        Revision from “time to
                                         time”
                                         –   USP MMG v2.0 (2006)
                                         –   USP MMG v3.0 (2007)
                                         –   USP MMG v4.0 (2008)
                                         –   USP MMG v5.0 (2011)
                                         –   USP MMG v6.0 (2014)
Arch Intern Med 2006; 145:448-453.
                                                                        31
USP Medicare Model Guidelines

 USP   MMG are….                      USP   MMG are not….

  √Structural model of categories       ≠ Formulary or list of essential
   and classes                            medications

  √Part of a CMS Part D formulary       ≠ Mandated in their entirety (plans
   check that requires 2 drugs from       can adjust their formulary
   each category/class                    category/class names)

  √Therapeutically driven by FDA        ≠ Drug classification based solely
   indications xxxxxxxxxx                 upon pharmacology/chemistry

  √Specific to Part D drugs and         ≠ Inclusive of all medications or
   Medicare Beneficiaries                 patients

                                                                              32
ACA Essential Health Benefits

   ACA requires health plans to cover “Essential Health Benefits” (EHB)
    within 10 benefit categories, including prescription drugs

   HHS Final Rule (2/25/13) cites USP Medicare Model Guidelines
    – “…in order to comply with the requirement to cover EHB, a plan would cover
      at least the greater of:
          (1) One drug in every USP category and class; or
          (2) the same number of drugs in each category
          and class as the EHB-benchmark plan. “

   For 2014-2015, HHS makes use of
    USP Medicare Model Guidelines v5.0

                                                                                   33
Looking ahead….

   Expert Panels to address therapeutic information needs
    expressed by USP Convention membership
             • Information and decision support for drug shortages
             • Biologic products
             • Precision medicine

       Data collected by the University of Utah Drug Information
       Service. Data for 2012 are through Dec 31, 2012.

                                                                     34
Opportunities at USP

                       35
Council of Experts & Expert Committees

   Council of Experts
    – oversees USP's scientific and standards-setting decisions
   Expert Committees
    – responsible for developing and revising USP standards that comprise its
      seven compendia
   Expert Panel
    – formed to provide additional expertise on a particular compendial topic,
      thereby supplementing Expert Committee expertise

   Call for Candidate for 2015-2020 Convention Cycle
    – Deadline for Application:       Jan 1, 2015
    – http://uspgo.to/call-candidates.

                                                                                 36
Summer Internship Program

   Offers students of chemistry, pharmaceutical sciences, and related science
    disciplines, the fulfilling opportunity to work on a defined project that expands
    and enhances USP's core strategic initiatives focusing on the following areas:
    –   Healthcare Quality Standards
    –   Reference Standards Laboratory—Quality of Manufactured Medicines
    –   Global Health Impact Program—Quality of Medicines
    –   Excipients

   Duration:       12 weeks, 37.5 hour work week
   Location:       U.S. Pharmacopeia Headquarters (Rockville, MD)
   Dates:          May 26, 2014 – August 15, 2014

   More information can be found at
    http://www.usp.org/about-usp/careers/internship-fellowship-programs

                                                                                        37
Global Fellowship Awards Program

   Promotes research in areas relating to standards for medicines, foods, and
    dietary supplements and their use
   USP Global Fellowship Awards of up to $50,000 are presented to the students
    whose proposed research directly address a specific USP scientific or research
    need.

   Eligibility
    – Have been accepted for full-time study in a Ph.D. or Pharm.D. program
    – Have been accepted to a Fellowship Program;
    – Or have been awarded a postdoctoral research (non-faculty) appointment.

   Application Deadline:              May 2, 2014

   More information can be found at
    http://www.usp.org/about-usp/careers/internship-fellowship-programs

                                                                                     38
Career Opportunities

   Being a part of USP means belonging to a diverse culture made up of more than
    800 talented professionals working together at five international locations.

   We share our expertise in science, IT, human resources, quality assurance,
    communications, administrative management, and more...all to support an
    overall mission dedicated to making a difference by providing standards and
    programs that help improve the quality of medicines, dietary supplements, and
    foods worldwide.

   Current openings can be found at:
    https://uspcareers.silkroad.com/
    uspext/EmploymentListings/
    EmploymentListingsUSP.html

                                                                                    39
My pathway to USP

                    40
You can also read